Amylyx Pharmaceuticals (AMLX) Interest & Investment Income (2021 - 2026)

Amylyx Pharmaceuticals' Interest & Investment Income history runs 6 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• On a quarterly basis, Interest & Investment Income rose 15.19% year-over-year to $2.6 million in Q1 2026; TTM through Mar 2026 was $9.6 million, a 17.7% decrease from a year earlier, with the FY2025 full-year figure at $9.3 million, down 32.64% from the prior year.
• Interest & Investment Income retreated to $2.6 million in Q1 2026 per AMLX's latest filing, from $3.3 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $4.4 million in Q4 2023 and bottomed at $131000.0 in Q1 2022.
• The 5-year median for Interest & Investment Income is $3.1 million (2024), against an average of $2.7 million.
• Across the five-year window, Interest & Investment Income soared 40100.0% in 2022 and plunged 51.83% in 2025, its largest moves.
• Year by year, Interest & Investment Income stood at $3.2 million in 2022, then soared by 38.45% to $4.4 million in 2023, then slumped by 47.01% to $2.3 million in 2024, then jumped by 42.06% to $3.3 million in 2025, then dropped by 21.88% to $2.6 million in 2026.
• Per Business Quant, the three latest AMLX Interest & Investment Income figures stand at $2.6 million (Q1 2026), $3.3 million (Q4 2025), and $1.8 million (Q3 2025).